Skip to main content
. 2022 Feb 6;59(3):106545. doi: 10.1016/j.ijantimicag.2022.106545

Fig. 5.

Fig 5

Forest plot of the comparison of the risk of adverse events between sofosbuvir-based treatment and comparators.